<?xml version='1.0' encoding='utf-8'?>
<document id="30541878"><sentence text="Pharmacokinetics, Metabolism, and Excretion of [14C]Esaxerenone, a Novel Mineralocorticoid Receptor Blocker in Humans."><entity charOffset="47-63" id="DDI-PubMed.30541878.s1.e0" text="[14C]Esaxerenone" /></sentence><sentence text="Esaxerenone (CS-3150) is a novel, nonsteroidal, selective mineralocorticoid receptor blocker"><entity charOffset="0-11" id="DDI-PubMed.30541878.s2.e0" text="Esaxerenone" /><entity charOffset="13-20" id="DDI-PubMed.30541878.s2.e1" text="CS-3150" /><pair ddi="false" e1="DDI-PubMed.30541878.s2.e0" e2="DDI-PubMed.30541878.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30541878.s2.e0" e2="DDI-PubMed.30541878.s2.e1" /></sentence><sentence text=" The absorption, metabolism, distribution, and excretion of esaxerenone were assessed in in vitro studies and in a clinical study, where [14C]esaxerenone (150 Î¼Ci/20 mg) was administered orally to six healthy male subjects"><entity charOffset="60-71" id="DDI-PubMed.30541878.s3.e0" text="esaxerenone" /><entity charOffset="137-153" id="DDI-PubMed.30541878.s3.e1" text="[14C]esaxerenone" /><pair ddi="false" e1="DDI-PubMed.30541878.s3.e0" e2="DDI-PubMed.30541878.s3.e0" /><pair ddi="false" e1="DDI-PubMed.30541878.s3.e0" e2="DDI-PubMed.30541878.s3.e1" /></sentence><sentence text=" The plasma concentrations of esaxerenone and its metabolites (M4, M11, and M1) were measured using liquid chromatography-tandem mass spectrometry"><entity charOffset="30-41" id="DDI-PubMed.30541878.s4.e0" text="esaxerenone" /></sentence><sentence text=" The recovery of radioactivity was 92" /><sentence text="5%, with 38" /><sentence text="5% and 54" /><sentence text="0% excreted in the urine and feces, respectively" /><sentence text=" The half-life of radioactivity in blood and plasma was approximately 30 hours, similar to that of the unchanged form in plasma" /><sentence text=" The blood-to-plasma ratio was 0" /><sentence text="628, demonstrating low partitioning to blood components" /><sentence text=" In plasma, esaxerenone was the most abundant moiety (40"><entity charOffset="12-23" id="DDI-PubMed.30541878.s12.e0" text="esaxerenone" /></sentence><sentence text="8%), followed by O-glucuronide (21"><entity charOffset="17-30" id="DDI-PubMed.30541878.s13.e0" text="O-glucuronide" /></sentence><sentence text="4%; M4), acyl-glucuronide of amide-bond hydrolysate (8"><entity charOffset="9-25" id="DDI-PubMed.30541878.s14.e0" text="acyl-glucuronide" /><entity charOffset="29-34" id="DDI-PubMed.30541878.s14.e1" text="amide" /><pair ddi="false" e1="DDI-PubMed.30541878.s14.e0" e2="DDI-PubMed.30541878.s14.e0" /><pair ddi="false" e1="DDI-PubMed.30541878.s14.e0" e2="DDI-PubMed.30541878.s14.e1" /></sentence><sentence text="0%; M11), and the deshydroxyethyl form (1"><entity charOffset="18-33" id="DDI-PubMed.30541878.s15.e0" text="deshydroxyethyl" /></sentence><sentence text="7%; M1)" /><sentence text=" In vitro studies showed that esaxerenone was a substrate of CYP3A and multiple UDP-glucuronosyltransferase isoforms"><entity charOffset="30-41" id="DDI-PubMed.30541878.s17.e0" text="esaxerenone" /></sentence><sentence text=" Oxidation contributed approximately 30% to its clearance, as indicated by the excretion ratio of oxidized metabolites into urine and feces" /><sentence text=" Caco-2 studies showed that esaxerenone was a substrate of P-glycoprotein and breast cancer resistance protein; however, the excretion ratios of the unchanged form in the feces and urine were 18"><entity charOffset="28-39" id="DDI-PubMed.30541878.s19.e0" text="esaxerenone" /></sentence><sentence text="7% and 1" /><sentence text="6%, respectively, indicating that these transporters were not important for the absorption and elimination of esaxerenone"><entity charOffset="110-121" id="DDI-PubMed.30541878.s21.e0" text="esaxerenone" /></sentence><sentence text=" Low urinary excretion of esaxerenone suggested that the plasma exposure of esaxerenone was not affected by renal dysfunction"><entity charOffset="26-37" id="DDI-PubMed.30541878.s22.e0" text="esaxerenone" /><entity charOffset="76-87" id="DDI-PubMed.30541878.s22.e1" text="esaxerenone" /><pair ddi="false" e1="DDI-PubMed.30541878.s22.e0" e2="DDI-PubMed.30541878.s22.e0" /><pair ddi="false" e1="DDI-PubMed.30541878.s22.e0" e2="DDI-PubMed.30541878.s22.e1" /></sentence><sentence text=" Multiple elimination pathways including oxidation, glucuronidation, and hydrolysis, and the low contribution of transporters, indicated limited drug-drug interaction potential" /><sentence text="" /></document>